Zenas BioPharma
ZBIO · Nasdaq · United States
Share price · ZBIO
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ZBIO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 6 Nov 2026+9.0%
- 8 Oct 2026-6.9%
Nothing announced by ZBIO that day or the session before.
- 24 Sep 2026-7.2%
Nothing announced by ZBIO that day or the session before.
- 1 Jul 2026+10.3%
Nothing announced by ZBIO that day or the session before.
- 25 Jun 2026+13.2%
Nothing announced by ZBIO that day or the session before.
- 12 Jun 2026+11.5%
Nothing announced by ZBIO that day or the session before.
- 4 May 2026+11.4%
Nothing announced by ZBIO that day or the session before.
- 12 Jan 2026+23.0%
Nothing announced by ZBIO that day or the session before.
- 5 Jan 2026-51.9%
Nothing announced by ZBIO that day or the session before.
- 22 Dec 2025+17.1%
Nothing announced by ZBIO that day or the session before.
Share of unusual movement by asset
For each asset, the share of ZBIO's own-move activity since 17 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Obexelimabevents and moves
| 2 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 30% |
| Other company news (earnings, financing, releases naming no asset) | — | 1% |
| Sessions with no dated event | — | 69% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | CD19 / FcγRIIbMonoclonal antibody | Systemic Lupus ErythematosusIgG4-Related Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (10)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $10M | $58M | $178M+ $408M short-term inv. | $109M-$58M operating cash flow | report ↗ |
View 9 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $1.0M | $63M | $197M+ $447M short-term inv. | $111M-$57M operating cash flow | report ↗ |
| 2026-Q1 | — | $60M | $500M+ $217M short-term inv. | $81M-$75M operating cash flow | report ↗ |
| 2025-Q3 | $0 | $34M | $116M+ $175M short-term inv. | $52M-$41M operating cash flow | report ↗ |
| 2025-Q2 | $0 | $43M | $44M+ $229M short-term inv. | $52M-$42M operating cash flow | report ↗ |
| 2025-Q1 | $10M | $35M | $197M+ $116M short-term inv. | $34M-$37M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $34M | $360M+ $27M short-term inv. | $39M-$31M operating cash flow | report ↗ |
| 2024-Q2 | $0 | $34M | $184M | $38M-$31M operating cash flow | report ↗ |
| 2024-Q1 | — | $23M | $37M | $28M-$19M operating cash flow | report ↗ |
| 2023-Q3 | $50M | $9.3M | $72M | — | report ↗ |
Annual history (4 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $10M | $168M | $111M+ $233M short-term inv. | $94M-$172M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 17 purchases ($11.4M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-01 | Oliger Christy J. · director | Award / grant (derivative) | 37,000 | — | — | Form 4 |
| 2026-06-15 | ENRIGHT PATRICK G · director | Award / grant (derivative) | 18,500 | — | — | Form 4 |
| 2026-06-15 | Boylan James P · director | Award / grant (derivative) | 18,500 | — | — | Form 4 |
| 2026-06-15 | Allen Patricia L · director | Award / grant (derivative) | 18,500 | — | — | Form 4 |
| 2026-06-15 | von Moltke Lisa · See Remarks | Award / grant (derivative) | 150,000 | — | — | Form 4 |
| 2026-06-15 | ORLOFF JOHN J · director | Award / grant (derivative) | 18,500 | — | — | Form 4 |
| 2026-06-15 | MOULDER LEON O JR · director, See Remarks | Award / grant (derivative) | 500,000 | — | — | Form 4 |
| 2026-06-15 | Lu Hongbo · director | Award / grant (derivative) | 18,500 | — | — | Form 4 |